On March 10, 2017 Spotlight Innovation Inc. (OTCQB: STLT) reported that its subsidiary Celtic Biotech has begun Part 2 of its Phase I dose escalation safety study, Crotoxin in Patients with Advanced Cancer using an Intravenous Route of Administration (Press release, Spotlight Innovation, MAR 10, 2017, View Source [SID1234518077]). ImmunoClin Ltd., a company specializing in clinical development, is the contract research organization (CRO) overseeing the study conduct. Schedule your 30 min Free 1stOncology Demo! Part 2 of the Phase I study uses a revised protocol designed to determine whether faster dose escalation can be attained in a shortened time frame without increased risk to patients. The trial is being conducted at the Department of Medical Oncology at Pitié-Salpêtrière Hospital in Paris under the direction of Principal Investigator Maria A. Gil-Delgado, MD, PhD. Dr. Gil-Delgado is a member of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper). Noted French oncologist David Khayat, MD, PhD, FASCO, a Board Member of ASCO (Free ASCO Whitepaper), is serving as Principal Scientific Advisor.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
John Krohn, Spotlight Innovation’s President and Chief Operating Officer, said, "Commencement of Part 2 of this study is a significant step in our cancer drug development program. Crotoxin is an important new potential treatment option for patients with advanced solid tumors, and we are pleased with our progress in the clinical trial process."
Oncology is one of four focus areas within Spotlight Innovation’s research and development pipeline; the others are chronic pain, Zika virus infection and spinal muscular atrophy (SMA).